Cystic fibrosis transmembrane conductance regulator: the NBF1+R (nucleotide-binding fold 1 and regulatory domain) segment acting alone catalyses a Co2+/Mn2+/Mg2+-ATPase activity markedly inhibited by both Cd2+ and the transition-state analogue orthovanadate
- 15 April 2003
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 371 (2) , 451-462
- https://doi.org/10.1042/bj20021318
Abstract
Cystic fibrosis (CF) is caused by mutations in the gene encoding CFTR (cystic fibrosis transmembrane conductance regulator), a regulated anion channel and member of the ATP-binding-cassette transporter (ABC transporter) superfamily. Of CFTR's five domains, the first nucleotide-binding fold (NBF1) has been of greatest interest both because it is the major ‘hotspot’ for mutations that cause CF, and because it is connected to a unique regulatory domain (R). However, attempts have failed to obtain a catalytically active NBF1+R protein in the absence of a fusion partner. Here, we report that such a protein can be obtained following its overexpression in bacteria. The pure NBF1+R protein exhibits significant ATPase activity [catalytic-centre activity (turnover number) 6.7min−1] and an apparent affinity for ATP (Km, 8.7μM) higher than reported previously for CFTR or segments thereof. As predicted, the ATPase activity is inhibited by mutations in the Walker A motif. It is also inhibited by vanadate, a transition-state analogue. Surprisingly, however, the best divalent metal activator is Co2+, followed by Mn2+ and Mg2+. In contrast, Ca2+ is ineffective and Cd2+ is a potent inhibitor. These novel studies, while demonstrating clearly that CFTR's NBF1+R segment can act independently as an active, vanadate-sensitive ATPase, also identify its unique cation activators and a new inhibitor, thus providing insight into the nature of its active site.Keywords
This publication has 54 references indexed in Scilit:
- Functional analysis of the C-terminal boundary of the second nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator and structural implicationsBiochemical Journal, 2002
- Structural Biology of Rad50 ATPaseCell, 2000
- ATP Hydrolysis by a CFTR Domain: Pharmacology and Effects of G551D MutationBiochemical and Biophysical Research Communications, 2000
- Cystic Fibrosis Transmembrane Conductance Regulator: Solution Structures of Peptides Based on the Phe508 Region, the Most Common Site of Disease-Causing ΔF508 Mutation,Biochemistry, 1999
- Novel Insights into the Chemical Mechanism of ATP SynthaseJournal of Biological Chemistry, 1997
- Cystic Fibrosis Transmembrane Conductance Regulator: The First Nucleotide Binding Fold Targets the Membrane with Retention of Its ATP Binding FunctionBiochemistry, 1997
- Association of Domains within the Cystic Fibrosis Transmembrane Conductance RegulatorBiochemistry, 1997
- ATP SynthasePublished by Elsevier ,1996
- The First Nucleotide Binding Fold of the Cystic Fibrosis Transmembrane Conductance Regulator Can Function as an Active ATPaseJournal of Biological Chemistry, 1995
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970